Member Article

North East pharmaceuticals outfit to expand into Japan and US

Newcaslte-headquartered Aesica Pharmaceuticals has signed a collaborative agreement with Japaneses drug research outfit CMIC HOLDINGS to pursue international expansion across Europe, Japan and the US.

The memorandum of understanding sets out mutually beneficial opporunties in Japan and Europe and also begins a collaborative development in the US.

CMIC is looking to grow outside of Japan and Aesica’s customer base provide a good network for the firm while CMIC customers offer Aesica opportunity in Japan.

Dr Robert Hardy, CEO of Aesica said: “This agreement will provide a tremendous opportunity to develop business and commercial opportunities for our customers in the Japanese market and in the US, whilst providing solid scope for us to expand our market share in these regions. We look forward to forging an extremely close working relationship and partnership between our two companies”.

Kazuo Nakamura, chairman and CEO of CMIC added: “There are tremendous synergies between CMIC and Aesica which will be exploited to the full commercial benefit of customers of each company. Whilst CMIC is a leading Japanese, full service contract development and manufacturer of formulated products for the pharmaceutical industry, with established manufacturing sites in Japan, Korea and the USA, Aesica is an international CDMO operating in the UK, Germany and Italy across both API and formulated products. The combined, European, Japanese and US commercial expertise and presence is enormous.”

This was posted in Bdaily's Members' News section by Tom Keighley .